128 related articles for article (PubMed ID: 19663703)
21. FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.
Smal MP; Rolevich AI; Polyakov SL; Krasny SA; Goncharova RI
Exp Oncol; 2014 Dec; 36(4):246-51. PubMed ID: 25537218
[TBL] [Abstract][Full Text] [Related]
22. Generation and characterization of monoclonal antibodies to TDRD7 protein.
Skorokhod O; Nemazanyy I; Breus O; Filonenko V; Panasyuk G
Hybridoma (Larchmt); 2008 Jun; 27(3):211-6. PubMed ID: 18582216
[TBL] [Abstract][Full Text] [Related]
23. Alteration of cell-cell and cell-matrix adhesion in urothelial cells: an oncogenic mechanism for mutant FGFR3.
di Martino E; Kelly G; Roulson JA; Knowles MA
Mol Cancer Res; 2015 Jan; 13(1):138-48. PubMed ID: 25223521
[TBL] [Abstract][Full Text] [Related]
24. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
Iyer G; Milowsky MI
Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
[TBL] [Abstract][Full Text] [Related]
25. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
[TBL] [Abstract][Full Text] [Related]
26. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
[TBL] [Abstract][Full Text] [Related]
27. Expression of adaptor protein Ruk/CIN85 isoforms in cell lines of various tissue origins and human melanoma.
Mayevska O; Shuvayeva H; Igumentseva N; Havrylov S; Basaraba O; Bobak Y; Barska M; Volod'ko N; Baranska J; Buchman V; Drobot L
Exp Oncol; 2006 Dec; 28(4):275-81. PubMed ID: 17285110
[TBL] [Abstract][Full Text] [Related]
28. Generation of Domain-Specific Monoclonal Antibodies Against Human Glutaredoxin3.
Dai X; Li Y; Sun X; Cai K; Mao Q; Xia H
Monoclon Antib Immunodiagn Immunother; 2016 Dec; 35(6):285-292. PubMed ID: 27923109
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody.
Yin Y; Ren X; Smith C; Guo Q; Malabunga M; Guernah I; Zhang Y; Shen J; Sun H; Chehab N; Loizos N; Ludwig DL; Ornitz DM
Dis Model Mech; 2016 May; 9(5):563-71. PubMed ID: 27056048
[TBL] [Abstract][Full Text] [Related]
30. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.
Billerey C; Chopin D; Aubriot-Lorton MH; Ricol D; Gil Diez de Medina S; Van Rhijn B; Bralet MP; Lefrere-Belda MA; Lahaye JB; Abbou CC; Bonaventure J; Zafrani ES; van der Kwast T; Thiery JP; Radvanyi F
Am J Pathol; 2001 Jun; 158(6):1955-9. PubMed ID: 11395371
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway.
Johnson MD; O'Connell MJ; Pilcher W; Reeder JE
J Neurosurg; 2010 May; 112(5):934-9. PubMed ID: 19698046
[TBL] [Abstract][Full Text] [Related]
32. FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth.
Du X; Wang QR; Chan E; Merchant M; Liu J; French D; Ashkenazi A; Qing J
Cancer Res; 2012 Nov; 72(22):5843-55. PubMed ID: 23019225
[TBL] [Abstract][Full Text] [Related]
33. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.
Fischbach A; Rogler A; Erber R; Stoehr R; Poulsom R; Heidenreich A; Schneevoigt BS; Hauke S; Hartmann A; Knuechel R; Veeck J; Gaisa NT
Histopathology; 2015 Apr; 66(5):639-49. PubMed ID: 24898159
[TBL] [Abstract][Full Text] [Related]
34. Expression of the fibroblast growth factor receptor-1 in human normal tissues and tumors determined by a new monoclonal antibody.
Morikawa Y; Ishihara Y; Tohya K; Kakudo K; Seo MK; Matsuura N
Arch Pathol Lab Med; 1996 May; 120(5):490-6. PubMed ID: 8639054
[TBL] [Abstract][Full Text] [Related]
35. MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer.
Du X; Lin BC; Wang QR; Li H; Ingalla E; Tien J; Rooney I; Ashkenazi A; Penuel E; Qing J
Clin Cancer Res; 2014 Dec; 20(24):6324-35. PubMed ID: 25326231
[TBL] [Abstract][Full Text] [Related]
36. Expression of intracellular domain of epidermal growth factor receptor and generation of its monoclonal antibody.
Lin Y; Liu Z; Jiang J; Jiang Z; Ji Y; Sun B
Cell Mol Immunol; 2004 Apr; 1(2):137-41. PubMed ID: 16212901
[TBL] [Abstract][Full Text] [Related]
37. FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.
Foth M; Ismail NFB; Kung JSC; Tomlinson D; Knowles MA; Eriksson P; Sjödahl G; Salmond JM; Sansom OJ; Iwata T
J Pathol; 2018 Nov; 246(3):331-343. PubMed ID: 30043421
[TBL] [Abstract][Full Text] [Related]
38. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis.
L'Hôte CG; Knowles MA
Exp Cell Res; 2005 Apr; 304(2):417-31. PubMed ID: 15748888
[TBL] [Abstract][Full Text] [Related]
39. Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium.
Murgue B; Tsunekawa S; Rosenberg I; deBeaumont M; Podolsky DK
Cancer Res; 1994 Oct; 54(19):5206-11. PubMed ID: 7923141
[TBL] [Abstract][Full Text] [Related]
40. Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas.
Dai H; Holm R; Kristensen GB; Abeler VM; Børresen-Dale AL; Helland A
Anal Cell Pathol; 2001; 23(2):45-9. PubMed ID: 11904459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
